Association of Vascular Endothelial Growth Factor Gene Polymorphism With Renal Cell Carcinoma Risk

Abstract

The conclusion of the relationship between vascular endothelial growth factor gene polymorphism and renal cell carcinoma risk was inconsistent. This study was performed to assess the relationship between vascular endothelial growth factor gene polymorphism and renal cell carcinoma risk using meta-analysis. The association studies were identified from PubMed, Embase, and Web of Science, and eligible studies were included and calculated. Ten studies were included for this meta-analysis. vascular endothelial growth factor (VEGF) +405G > CC allele and GG genotype were associated with renal cell carcinoma risk for overall populations in this meta-analysis (C allele: odds ratio = 1.18, 95% confidence interval: 1.05-1.33, P = .004; CC genotype: odds ratio = 1.20, 95% confidence interval: 0.96-1.50, P = .12; GG genotype: odds ratio = 0.79, 95% confidence interval: 0.67-0.93, P = .004). Furthermore, VEGF +936C>T gene polymorphism and VEGF −2578 C>A gene polymorphism were associated with renal cell carcinoma risk for overall populations (+936C>T: T allele: odds ratio = 1.16, 95% confidence interval: 1.05-1.29, P = .004; TT genotype: odds ratio = 1.25, 95% confidence interval: 1.02-1.52, P = .03; CC genotype: odds ratio = 0.86, 95% confidence interval: 0.75-0.98, P = .03; −2578 C>A: A allele: odds ratio = 1.26, 95% confidence interval: 1.15-1.38, P < .00001; AA genotype: odds ratio = 1.39, 95% confidence interval: 1.16-1.67, P = .0004; CC genotype: odds ratio = 0.75, 95% confidence interval: 0.61-0.92, P = .006). However, VEGF −634G>C, VEGF −460T>C, VEGF −1154 G>A, and VEGF +1612 G>A gene polymorphisms were not associated with renal cell carcinoma risk. In conclusion, VEGF +405G>CC allele and GG genotype, VEGF +936C>T gene polymorphism, and VEGF −2578 C>A gene polymorphism were associated with renal cell carcinoma risk for overall populations. However, more studies should be performed to assess this relationship in the future.

The relationship between VEGF-460(T>C) polymorphism and cancer risk: A systematic review and meta-analysis based on 46 reports

“…[85] Both meta-findings demonstrate that this SNP is unrelated to renal cell carcinoma. [87,88] And J. Zhao et al conclude that VEGF-460 enhances the risk of osteosarcoma. [91] As for ovarian, gastric, oral, and prostate cancers, there is no evidence of VEGF-460 being related to them.…”

“…Several investigators have conducted meta-analyses to evaluate this link comprehensively. [79][80][81][82][83][84][85][86][87][88][89][90][91][92] Their meta-analysis was almost only for single cancer with small sample sizes. As far as we know, only one meta-analysis of VEGF-460 polymorphisms and overall cancer risk has been published, [79] but it was published earlier and included less studies.…”

Circ_0008717 promotes renal cell carcinoma progression by upregulating FBXO17 via targeting miR‐217

“…19 Numerous valuable perspectives about RCC pathogenesis have been described, such as abnormal activation of the mammalian target of rapamycin pathway, aberrant expression of genes and regulatory activity of non-coding RNAs. [20][21][22] CircRNA, belonging to non-coding RNAs, is poorly investigated in RCC. Here, we reported a circRNA, circ_0008717, which plays crucial roles in RCC development by modulating RCC cell proliferation, migration, invasion and glycolysis in vitro, as well as tumorigenesis in vivo.…”

“…The therapy of RCC is still a clinical challenge for clinicians, especially for patients with metastatic RCC 19 . Numerous valuable perspectives about RCC pathogenesis have been described, such as abnormal activation of the mammalian target of rapamycin pathway, aberrant expression of genes and regulatory activity of non‐coding RNAs 20–22 . CircRNA, belonging to non‐coding RNAs, is poorly investigated in RCC.…”

Association of Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms With Gastric Cancer and Its Development, Prognosis, and Survival

“…5 Present data indicate that VEGF gene polymorphisms were associated with the risk of cancers, such as bladder cancer, 6 papillary thyroid carcinoma, 7 lung cancer, 8 hepatocellular carcinoma, 9 and renal cell carcinoma. 10 The VEGF pathway also plays a prominent role in the growth and progression of human cancer, including gastric cancer. 11 Current evidence shows that VEGF plays a role in the pathogenesis of gastric cancer.…”